Durvalumab fda approved for stage 3 lung cancer

[D.ap]

“On Friday, February 16, 2018, the FDA approved durvalumab (IMFINZI ®, AstraZeneca), an anti-PD-L1 checkpoint immunotherapy, for patients with unresectable, stage III non-small cell lung cancer (NSCLC) that hasn’t progressed after prior chemo-radiation treatment. Importantly, this approval covers patients regardless of their PD-L1 expression status.”




https://cancerresearch.org/blog/februar ... a-approval

[D.ap]

There are clinical trials with Duravalumab inc showing success with ASPS.
Hope some day we will know the end results of this immune drug treating ASPS. : )

http://www.cureasps.org/forum/viewtopic ... mab#p11375

[cachabamba10]

This is really good news, thank you Debbie for posting this. It might help for insurance to cover it as well.

[Olga]

Mario - when are you going to have a scan for the follow up after your Durvalumab trial has ended? Most of the ICI (immune checkpoint inhibitors) drugs trials are limited by 2 years and the discontinuation after. I am wondering what is the procedure to follow up? The re-challenge by the same drug was shown to have a good response rate after the discontinuation in the patients previously responded but as you noted correctly there is an issue with the insurance for the off label approval.

[D.ap]

Hope all is well Mario :)

Love